Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator

• Ngā kaituhi matua: Jia Miao (Author), Ping Fu (Author), Shuang Ren (Author), Chao Hu (Author), Ying Wang (Author), Chengfeng Jiao (Author), Ping Li (Author), Yu zhao (Author), Cui Tang (Author), Yuli Qian (Author), Rong Yang (Author), Yanli Dong (Author), Jing Rong (Author), Yaohui Wang (Author), Xiaowei Jin (Author), Yu Sun (Author), Li Chen (Author)
• Hōputu: Pukapuka
• I whakaputaina: Wiley, 2022-02-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin's pharmacokineti...